Astra’s Caspian study is the star of next week’s World Lung conference, which has also given targeted approaches important supporting roles.
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
Continued interest in the Sting pathway might come as a surprise, though secrecy suggests that asset prices are failing.
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
After last year’s flop of Prothena’s NEOD001, Takeda’s Ninlaro fails to treat the underlying cause of the non-genetic form of this disease.
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
Biogen needs a win with its Tecfidera follow-on, while Kalvista hopes to make HAE where Biocryst failed.
Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
A look at sector share prices in the opening three months of 2019 reveals a resurgent big pharma and a strong showing from the world’s other large drug makers, with US…